Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

Live Evaluations

Prurigo Nodularis: Managing the ‘Itch-Scratch Cycle’ with Biologics

About

Prurigo Nodularis: Managing the ‘Itch-Scratch Cycle’ with Biologics

This activity is supported by educational grants from Galderma and Sanofi and Regeneron Pharmaceuticals.

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Describe the impact of PN on patient quality of life, including sleep quality and mental health

  • Review efficacy and safety data for approved and emerging biologics to manage PN

  • Discuss patient-centered strategies for integrating new and emerging biologics for PN into clinical care

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Raj
Raj Chovatiya, MD, PhD

Assistant Professor, Director of Center for Eczema and Itch 
Northwestern University Feinberg School of Medicine
Chicago, IL

Sarina
Sarina Elmariah, MD, PhD, MPH

Director, UCSF Itch and Neurosensory Center 
Associate Professor of Dermatology
University of California San Francisco​ 
San Francisco, CA​

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Raj Chovatiya, MD, PhD

Consultant: AbbVie, Arcutis, Arena, Argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, L’Oréal, National Eczema Association, Pfizer Inc., Regeneron, Sanofi, and UCB

Speakers’ Bureau or Honoraria: AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer Inc., Regeneron, Sanofi, and UCB

Sarina B. Elmariah, MD, PhD, MPH

Advisory Board: Bellus Health, Galderma, Pfizer, Sanofi Regeneron, Trevi Therapeutics

Speaker's Bureau: Eli Lilly, Pfizer

Ownership Interest: Frontier Bio

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved